Caitong International Asset Management Co. Ltd Takes Position in Hims & Hers Health, Inc. $HIMS

Caitong International Asset Management Co. Ltd acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) in the second quarter, HoldingsChannel reports. The institutional investor acquired 28,892 shares of the company’s stock, valued at approximately $1,440,000. Hims & Hers Health makes up approximately 1.0% of Caitong International Asset Management Co. Ltd’s portfolio, making the stock its 18th largest position.

A number of other hedge funds also recently made changes to their positions in HIMS. Geneos Wealth Management Inc. acquired a new position in shares of Hims & Hers Health in the 1st quarter valued at $30,000. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in shares of Hims & Hers Health during the 1st quarter worth about $41,000. Larson Financial Group LLC increased its position in shares of Hims & Hers Health by 47.7% during the 1st quarter. Larson Financial Group LLC now owns 1,419 shares of the company’s stock worth $42,000 after purchasing an additional 458 shares in the last quarter. Webster Bank N. A. increased its position in shares of Hims & Hers Health by 229.1% during the 2nd quarter. Webster Bank N. A. now owns 905 shares of the company’s stock worth $45,000 after purchasing an additional 630 shares in the last quarter. Finally, Tsfg LLC acquired a new stake in shares of Hims & Hers Health during the 1st quarter worth about $46,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Insider Activity

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 60,000 shares of Hims & Hers Health stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the completion of the transaction, the insider directly owned 169,940 shares of the company’s stock, valued at $9,105,385.20. The trade was a 26.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 660,000 shares of Hims & Hers Health stock in a transaction on Thursday, August 7th. The stock was sold at an average price of $50.58, for a total transaction of $33,382,800.00. Following the transaction, the chief executive officer directly owned 2,214,769 shares of the company’s stock, valued at approximately $112,023,016.02. This trade represents a 22.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,432,206 shares of company stock valued at $74,248,448 in the last ninety days. Corporate insiders own 13.71% of the company’s stock.

Hims & Hers Health Price Performance

NYSE HIMS opened at $48.51 on Friday. The company has a market capitalization of $10.96 billion, a PE ratio of 60.63, a price-to-earnings-growth ratio of 3.29 and a beta of 2.25. Hims & Hers Health, Inc. has a 12-month low of $18.33 and a 12-month high of $72.98. The firm’s 50 day moving average is $51.08 and its 200-day moving average is $49.34. The company has a quick ratio of 4.46, a current ratio of 4.98 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The firm had revenue of $544.83 million for the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.Hims & Hers Health’s quarterly revenue was up 72.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on HIMS. Weiss Ratings reiterated a “hold (c+)” rating on shares of Hims & Hers Health in a research report on Tuesday, October 14th. Zacks Research lowered shares of Hims & Hers Health from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 19th. Wall Street Zen cut shares of Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Canaccord Genuity Group restated a “buy” rating and set a $68.00 price objective on shares of Hims & Hers Health in a report on Friday, September 12th. Finally, Truist Financial cut their price target on shares of Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating on the stock in a research note on Monday, August 18th. Two analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Reduce” and a consensus price target of $38.92.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.